Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors

Korábbi kezelés

• Inability to take study medications

Más betegség

• Evidence of interstitial lung disease or active, non-infectious pneumonitis.
• Active infection requiring systemic therapy.
• Active Hepatitis B or C.
• Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Laborértékek

• Prior EGFR TKI or platinum-doublet therapy for advanced stage NSCLC. Prior (neo)adjuvant treatments are allowed when the last administration is one year or more.

Egyéb

• Inability to provide informed consent
• Patients with symptomatic or unstable CNS metastases
• Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit.

• Histologically confirmed NSCLC, positive for non-exon20insertion uncommon EGFR mutations that are eligible for afatinib therapy in first line
• WHO PS 0-2
• Be willing and able to provide written informed consent for the trial.
• Be above 18 years of age on day of signing informed consent.
• Patients must have radiological measurable disease
• Demonstrate adequate organ function, as deemed acceptable by the treating physician in the context of metastatic NSCLC.